If you made any changes in Pure these will be visible here soon.

Research Output 2018 2019

2019

Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

Vanoli, E., Montano, N., De Angelis, G., Badilini, F., Mirabella, M., Bonavita, S., Patti, F., Bianco, A., Sparaco, M., Chisari, C., Laroni, A., Frigerio, F., Bartezaghi, M., Rossi, S., Turrini, R. & Mancardi, G., 2019, In : Journal of the Neurological Sciences. 405, 116423.

Research output: Contribution to journalArticle

Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

Vanoli, E., Montano, N., De Angelis, G., Badilini, F., Mirabella, M., Bonavita, S., Patti, F., Bianco, A., Sparaco, M., Chisari, C., Laroni, A., Frigerio, F., Bartezaghi, M., Rossi, S., Turrini, R. & Mancardi, G., Oct 15 2019, In : Journal of the Neurological Sciences. 405, 116423.

Research output: Contribution to journalArticle

Relapsing-Remitting Multiple Sclerosis
Electrocardiography
Heart Rate
Sphingosine
Fingolimod Hydrochloride

Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: An Italian multicenter study

Annunziata, P., Masi, G., Cioni, C., Gastaldi, M., Marchioni, E., D'amico, E., Patti, F., Laroni, A., Mancardi, G., Vitetta, F. & Sola, P., Jun 22 2019, In : Neurological Sciences. 40, 7, p. 1383-1391 8 p.

Research output: Contribution to journalArticle

Transverse Myelitis
Multicenter Studies
Spinal Cord Diseases
Retrospective Studies

Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study

Annunziata, P., Masi, G., Cioni, C., Gastaldi, M., Marchioni, E., D’amico, E., Patti, F., Laroni, A., Mancardi, G., Vitetta, F. & Sola, P., Jul 1 2019, In : Neurological Sciences. 40, 7, p. 1383-1391 9 p.

Research output: Contribution to journalArticle

Transverse Myelitis
Multicenter Studies
Spinal Cord Diseases
Retrospective Studies

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico, M., De Mercanti, S. F., Signori, A., Iudicello, M., Cordioli, C., Signoriello, E., Lus, G., Bonavita, S., Lavorgna, L., Maniscalco, G. T., Curti, E., Lorefice, L., Cocco, E., Nociti, V., Mirabella, M., Baroncini, D., Mataluni, G., Landi, D., Petruzzo, M., Lanzillo, R. & 8 others, Gandoglia, I., Laroni, A., Frangiamore, R., Sartori, A., Cavalla, P., Costantini, G., Sormani, M. P. & Capra, R., Jan 1 2019, (Accepted/In press) In : Neurotherapeutics.

Research output: Contribution to journalArticle

Progressive Multifocal Leukoencephalopathy
Natalizumab
Appointments and Schedules
Cohort Studies
Retrospective Studies

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey

Lavorgna, L., Esposito, S., Lanzillo, R., Sparaco, M., Ippolito, D., Cocco, E., Fenu, G., Borriello, G., De Mercanti, S., Frau, J., Capuano, R., Trojsi, F., Rosa, L., Clerico, M., Laroni, A., Morra, V. B., Tedeschi, G. & Bonavita, S., Mar 1 2019, In : Journal of Neurology. 266, 3, p. 707-716 10 p.

Research output: Contribution to journalArticle

Multiple Sclerosis
Decision Making
Surveys and Questionnaires
Phenotype
Pregnancy

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S. M., Muraro, P. A., Oliveri, R. S., Radue, E. W., Sellner, J., Soelberg Sorensen, P., Sormani, M. P., Wuerfel, J. T., Battaglia, M. A., Freedman, M. S., Bonetti, B., Rush, C., Herrera, C., Ramo Tello, C., Miller, D. & 23 others, Szwajcer, D., Strunk, D., Wall, D., Aguera-Morales, E., Rohde, E., Dazzi, F., Comi, G., Martino, G., Izquierdo Ayuso, G., Rabinovitch, H., MacLean, H., Marriott, J., Racosta, J., Arab, L., Gimona, M., Introna, M., Blinkenberg, M., Aghdami, N., Ali, R., Vosoughi, R., Nicholas, R., Marrie, R. A. & Karimi, S., May 9 2019, In : Trials. 20, 1, 263.

Research output: Contribution to journalArticle

Open Access
Phase II Clinical Trials
Clinical Trials, Phase I
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Multiple Sclerosis

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

the i-MuST study group, Oct 1 2019, In : Journal of Neurology. 266, 10, p. 2440-2446 7 p.

Research output: Contribution to journalArticle

Multicenter Studies
Multiple Sclerosis
Cohort Studies
Lymphocyte Count
Therapeutics
2018
Pyramidal Tracts
Multiple Sclerosis
Corpus Callosum
Magnetic Resonance Imaging
Anisotropy

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Saccà, F., Lanzillo, R., Signori, A., Maniscalco, G. T., Signoriello, E., Lo Fermo, S., Repice, A., Annovazzi, P., Baroncini, D., Clerico, M., Binello, E., Cerqua, R., Mataluni, G., Bonavita, S., Lavorgna, L., Zarbo, I. R., Laroni, A., Rossi, S., Pareja Gutierrez, L., La Gioia, S. & 19 others, Frigeni, B., Barcella, V., Frau, J., Cocco, E., Fenu, G., Torri Clerici, V., Sartori, A., Rasia, S., Cordioli, C., Di Sapio, A., Pontecorvo, S., Grasso, R., Barrilà, C., Russo, C. V., Esposito, S., Ippolito, D., Bovis, F., Gallo, F. & Sormani, M. P., Jan 1 2018, (Accepted/In press) In : Multiple Sclerosis Journal.

Research output: Contribution to journalArticle

Multiple Sclerosis
Interferons
Safety
Patient Preference
Therapeutics

Enhancing natural killer cells is beneficial in multiple sclerosis – Yes

Laroni, A., Jan 1 2018, (Accepted/In press) In : Multiple Sclerosis Journal.

Research output: Contribution to journalArticle

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

the Italian Alemtuzumab Study Group, 2018, In : Journal of Neurology. 265, 12, p. 2851-2860 10 p.

Research output: Contribution to journalArticle

Multiple Sclerosis
Magnetic Resonance Imaging
Relapsing-Remitting Multiple Sclerosis
Recurrence
Therapeutics

Pregnancy decision-making in women with multiple sclerosis treated with natalizumabII: Maternal risks

Portaccio, E., Moiola, L., Martinelli, V., Annovazzi, P., Ghezzi, A., Zaffaroni, M., Lanzillo, R., Brescia Morra, V., Rinaldi, F., Gallo, P., Tortorella, C., Paolicelli, D., Pozzilli, C., De Giglio, L., Cavalla, P., Cocco, E., Marrosu, M. G., Solaro, C., Uccelli, A., Laroni, A. & 6 others, Pastò, L., Giannini, M., Trojano, M., Comi, G., Amato, M. P. & Society, MS. S. G. O. T. I. N., Mar 6 2018, In : Neurology. 90, 10, p. e832-e839

Research output: Contribution to journalArticle

Multiple Sclerosis
Decision Making
Mothers
Pregnancy
Recurrence
Serum Sickness
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Sulfamethoxazole Drug Combination Trimethoprim
Methylprednisolone